Targets › KLK3
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.
Hydrolyzes semenogelin-1 thus leading to the liquefaction of the seminal coagulum. (UniProt, P07288)
Open in Phaseline: the race on KLK3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1 | CEA, BRACHYURY, MUC1, KLK3, TBXT | Phase 2 | Adenocarcinoma; Metastatic Colorectal Cancer | Oct 2027 |
| Radiopharm Theranostics | 161Tb-RAD402 Radiolabeled anti-KLK3 monoclonal antibody targeting free prostate-specific antigen | KLK3 | Phase 1 | Castration-resistant Prostate Cancer | Nov 2028 |
Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Castration-resistant Prostate Cancer (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.